Андрология и генитальная хирургия. 2014; 15: 6-14
Медикаментозное лечение симптомов нижних мочевых путей у мужчин. Роль уроселективности в выборе препарата
https://doi.org/10.17650/2070-9781-2014-1-6-14Аннотация
У большинства пациентов расстройства мочеиспускания обусловлены как механическим, так и функциональным факторами. Своевременное выявление характера уродинамических нарушений, в первую очередь инфравезикальной обструкции и гиперактивности детрузора, у больных доброкачественной гиперплазией предстательной железы имеет важное практическое значение, так как без учета этого фактора существенно ухудшаются функциональные результаты хирургического лечения. α1-адреноблокаторы являются первой линией терапии для мужчин с симптомами нижних мочевых путей (СНМП). Они должны быть предложены пациентам с умеренными и тяжелыми СНМП. Выбор α1-адреноблокатора должен склоняться к более селективным представителям класса.
Селективность α-адреноблокатора обеспечивает наряду с высокой эффективностью низкий процент побочных реакций, особенно со стороны сердечно-сосудистой системы.
Так же как и α-адреноблокаторы, М-холиноблокаторы различаются по степени селективности в отношении воздействия именно на мочевой пузырь. Солифенацин более селективен в отношении мочевого пузыря, чем толтеродин и осибутинин. Селективность данного препарата по отношению к мочевому пузырю выражается относительно низкой частотой возникновения побочных эффектов, особенно сухости во рту, при его применении, а также возможностью длительной терапии. Комбинированное лечение α1-адреноблокатором с М-холиноблокатором может рассматриваться у пациентов с умеренными и тяжелыми СНМП с преобладанием симптомов наполнения, особенно если монотерапия не привела к облегчению симптомов.
Список литературы
1. Chapple C. R., Roehrborn C. G. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol 2006;49:651.
2. Oelke M., Bachmann A., Descazeaud A. et al. Guidelines on the Management of Male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO), 2013.
3. Ahlquist R. P. A study of the adrenotropic receptors. Am J Physiol 1948;153(3): 586–600.
4. Roehrborn C. G., Mc Connel J., Barry M. J. et al. Guideline on the Management of Benign Prostatic Hypertrophy, AUA. http://www.auanet.org / content /guidelines-and-quality-care / clinical-guidelines / main-reports / bph-management /preface_toc. pdf.
5. Milani S., Djavan B. Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: latest updated on α1-adrenoceptor antagonists. BJU Int 2005;95(Suppl 4):29–36.
6. Van Dijk M. M., de la Rosette J. J., Michel M. C. Tamsulosin – modified-release and oral controlled absorption system formulation in the treatment of benign prostatic hyperplasia. Therapy 2006;3:237–46.
7. Nickel J. C., Sander S., Moon T. D. A meta-analysis of the vascular-related safety profile and efficacy of alpha-adrenergic blockers for symptoms related to benign prostatic hyperplasia. Int J Clin Pract 2008;62:1547–59.
8. Michel M. C., Vrydag W. Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol 2006;147(Suppl 2):S88–119.
9. Guimaraes S., Moura D. Vascular adrenoceptors: an update. Pharmacol Rev 2001;53:319–56.
10. Rudner X. L., Berkowitz B. A., Booth J. V. et al. Subtype specific regulation of human vascular α1-adrenergic receptors by vessel bed and age. Circulation 1999;100:2336–43.
11. Michel M. C., Kenny B. A., Schwinn D. A. Classification of α1-adrenoceptor subtypes. Naunyn Schmiedeberg’s Arch Pharmacol 1995;352:1–10.
12. Zhu J., Taniguchi T., Takauji R. et al. Inverse agonism and neutral antagonism at a constitutively active alpha1a-adrenoceptor. Br J Pharmacol 2000;131:546–52.
13. Hein P., Goepel M., Cotecchia S., Michel M. C. A quantitative analysis of antagonism and inverse agonism at wild-type and constitutively active hamster α1B-adreno ceptors. Naunyn Schmiedeberg’s Arch Pharmacol 2001;363:34–9.
14. Zhang L., Taniguchi T., Tanaka T. et al. Alpha-1 adrenoceptor up-regulation induced by prazosin but not KMD-3213 or reserpine in rats. Br J Pharmacol 2002;135:1757–64.
15. Nagai A., Hara R., Yokoyama T. et al. Ejaculatory dysfunction caused by the new α1-blocker silodosin: a preliminary study to analyze human ejaculation using color Doppler ultrasonography. Int J Urol 2008;15:915–8.
16. Marks L. S., Gittelman M. C., Hill L. A. Rapid efficacy of the highly selective A1-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. J Urol 2009;181:2634–40.
17. Kawabe K., Yoshida M., Homma Y. Silodosin, a new a1A-adrenoceptorselective antagonist for treating benign prostatic hyperplasia: a results of a phase III randomized, placebo-controlled, double-blind study in Japanese men. BJU Int 2006;98:1019–24.
18. Speakman M. J., Snijder R. J., Anthonijs G., Doyle C. A. Patients on tamsulosin experiencing abnormal ejaculation choose to remain longer in clinical trials and have slightly better improvement in symptom score than other patients abstract. J Urol 2003;169(Suppl 4):334.
19. Roehrborn C. G., Lepor H., Kaplan S. A. et al. Retrograde ejaculation induced by silodosin is associated with greater urodynamic and symptomatic improvement in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. Podium presentation at the 85th annual meeting of the Western Section of the American Urological Association, October 25–29, 2009.
20. Лепор Г. Альфа-блокаторы: отбор на селективность. Истинно селективный альфа-блокатор. Урол сегодня 2013;3(25):3.
21. Говоров А. В. Альфа-блокаторы: отбор на селективность. Альфа-блокаторы: уроселективность по максимуму. Урол сегодня 2013;3(25):1–2.
22. Монторси Ф. Альфа-блокаторы: отбор на селективность. Альфа-блокаторы: наука в фокусе. Урол сегодня 2013;3(25):4.
23. Мельников А. В. Послеоперационная острая задержка мочеиспускания: Дис. … канд. мед. наук. М., 2002. 136 c.
24. Tatemichi S., Kobayashi K., Maezawa A. et al. α1-Adrenoceptor subtype selectivity and organ specifi city of silodosin (KMD-3213). Yakugaku Zasshi 2006;126:209–16.
25. Watanabe T., Ozono S., Kageyama S. A randomized crossover study comparing patient preference for tamsulosin and silodosin in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia. J Int Med Res 2011; 39(1):129–42.
26. Marks L. S., Gittelman M. C., Hill L. A. et al. Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. J Urol 2009;181(6):2634–40.
27. Chapple C., Montorsi F., Tammela T. et al.; European Silodosin Study Group. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe. Eur Urol 2011;3(59):342–52.
28. Montorsi F. Profile of silodosin. Eur Urol 2010;4(Suppl 9):491–5.
29. Яровой С. К. Силодозин – новый препарат группы селективных α1-адреноблокаторов. Экспер и клин урол 2012;3:57–62.
30. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Diuretic versus alpha-blocker as first-step antihypertensive therapy. Final results from the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Hypertension 2003;42:239–46.
31. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2002;288(23):2981–97.
32. Blaivas J., Marks B., Weiss J. et al. Differential diagnosis of overactive bladder in men. J Urol 2009;182(6):2814–7.
33. Abrams P. H., Farrar D. J., Turner-Warwick R. T. et al. The results of prostatectomy: a symptomatic and urodynamic analysis of 152 patients. J Urol 1979;121:640–2.
34. Гаджиева З. К. Уродинамические исследования в диагностике и лечении нарушений мочеиспускания: Дис. … д-ра мед. наук. М., 2009.
35. Тангриберганов М. Р. Особенности лечения доброкачественной гиперплазии предстательной железы в сочетании с клиническими симптомами гиперактивного мочевого пузыря: Дис. … канд. мед. наук. М., 2011.
36. Ohtake A., Ukai M., Hatanaka T. et al. In vitro and in vivo tissue selectivity profile of Solifenacin succinate (YM905) for urinary bladder over salivary gland in rats. Eur J Pharmacol 2004;492:243–50.
37. Chapple C., Herschornb S., Abrams P. et al. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers. Eur Urol 2009;56(3):534–41.
38. Abdel-Khalek M., Nabieh A., Ibrahiem E. Do muscarinic receptors of the prostate have a significant role in the pathophysiology of bladder outlet obstruction? phase 1 (in vitro) study. Eur Urol Suppl 2006;5(2):120.
39. Козырев С. В. Диагностика и лечение гиперактивного мочевого пузыря у больных доброкачественной гиперплазией предстательной железы: Дис. … канд. мед. наук. М., 2008.
40. Saito H., Yamada T., Oshima H. et al. A comparative study of the efficacy and safety of tamsulosin hydrochloride alone and combination of propiverine hydrochloride and tamsulosin hydrochloride in the benign prostatic hypertrophy with pollakisuria and / or urinary incontinence. Jpn J Urol Surg 1999;12:525–36.
41. Athanasopoulos A., Gyftopoulos K., Giannitsas K. et al. Combination treatment with an α-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J Urol 2003;169:2253–6.
42. Lee K. S., Kim D. Y., Kim J. C. et al. Combination treatment with propiverine hydrochloride plus doxazosin gits in men with overactive bladder coexisting benign prostatic obstruction: a prospective, randomized, controlled, multicenter study. ICS annual meeting, 2004 (abstr. 207).
43. Lee K. S., Choo M. S., Kim D. Y. et al. Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and
44. coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study. J Urol 2005;174:1334–8.
45. Kaplan S. A., Roehrborn C. G., Rovner E. S. et al. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA 2006;296 (19):2319–28.
46. MacDiarmid S.A., Peters K. M., Chen A. et al. Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study. Mayo Clin Proc 2008;83(9): 1002–10.
47. Drake M., Chapple C., van Kerrebroeck P. et al. Efficacy of combination therapy with tamsulosin OCAS and solifenacin in NEPTUNE: Results from a randomised, phase 3 trial in men with LUTS. Eur Urol 2012; EAU abstracts #746H.
Andrology and Genital Surgery. 2014; 15: 6-14
Drug treatment of lower urinary tract symptoms in males. Role uroselectivity in the choice of drug
https://doi.org/10.17650/2070-9781-2014-1-6-14Abstract
Most patients lower urinary tract symptoms (LUTS) caused both mechanical and functional factors. Timely identification of the nature of urodynamics, primarily of bladder outlet obstruction and detrusor overactivity, in patients with benign prostatic hyperplasia is of practical importance, since without this factor significantly worse functional outcome of surgical treatment. α1-adrenoblockers are the first line therapy for men with bothersome LUTS. They should be offered to patients with moderate to severe LUTS. Choosing α1-adrenoblocker should lean toward more selective class representatives. Selectivity α1-adrenoblocker provides high efficiency along with a low percentage of adverse effects, especially for cardiovascular system.
As well as α-adrenoblockers, M-cholinobloсkers varying degrees of selectivity of the impact is on the bladder. Solifenacin is more selective for the bladder than tolterodine and oxybutynin. The selectivity of the drug with respect to the bladder is reflected in the relatively low frequency of adverse effects, especially occurrence of dry mouth in its application, as well as the possibility of long term therapy. Combined treatment with α1-adrenoreceptor antagonist with M-cholinergic antagonists may be considered in patients with moderate to severe LUTS with a predominance of filling symptoms, especially if monotherapy led to relief of symptoms.
References
1. Chapple C. R., Roehrborn C. G. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol 2006;49:651.
2. Oelke M., Bachmann A., Descazeaud A. et al. Guidelines on the Management of Male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO), 2013.
3. Ahlquist R. P. A study of the adrenotropic receptors. Am J Physiol 1948;153(3): 586–600.
4. Roehrborn C. G., Mc Connel J., Barry M. J. et al. Guideline on the Management of Benign Prostatic Hypertrophy, AUA. http://www.auanet.org / content /guidelines-and-quality-care / clinical-guidelines / main-reports / bph-management /preface_toc. pdf.
5. Milani S., Djavan B. Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: latest updated on α1-adrenoceptor antagonists. BJU Int 2005;95(Suppl 4):29–36.
6. Van Dijk M. M., de la Rosette J. J., Michel M. C. Tamsulosin – modified-release and oral controlled absorption system formulation in the treatment of benign prostatic hyperplasia. Therapy 2006;3:237–46.
7. Nickel J. C., Sander S., Moon T. D. A meta-analysis of the vascular-related safety profile and efficacy of alpha-adrenergic blockers for symptoms related to benign prostatic hyperplasia. Int J Clin Pract 2008;62:1547–59.
8. Michel M. C., Vrydag W. Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol 2006;147(Suppl 2):S88–119.
9. Guimaraes S., Moura D. Vascular adrenoceptors: an update. Pharmacol Rev 2001;53:319–56.
10. Rudner X. L., Berkowitz B. A., Booth J. V. et al. Subtype specific regulation of human vascular α1-adrenergic receptors by vessel bed and age. Circulation 1999;100:2336–43.
11. Michel M. C., Kenny B. A., Schwinn D. A. Classification of α1-adrenoceptor subtypes. Naunyn Schmiedeberg’s Arch Pharmacol 1995;352:1–10.
12. Zhu J., Taniguchi T., Takauji R. et al. Inverse agonism and neutral antagonism at a constitutively active alpha1a-adrenoceptor. Br J Pharmacol 2000;131:546–52.
13. Hein P., Goepel M., Cotecchia S., Michel M. C. A quantitative analysis of antagonism and inverse agonism at wild-type and constitutively active hamster α1B-adreno ceptors. Naunyn Schmiedeberg’s Arch Pharmacol 2001;363:34–9.
14. Zhang L., Taniguchi T., Tanaka T. et al. Alpha-1 adrenoceptor up-regulation induced by prazosin but not KMD-3213 or reserpine in rats. Br J Pharmacol 2002;135:1757–64.
15. Nagai A., Hara R., Yokoyama T. et al. Ejaculatory dysfunction caused by the new α1-blocker silodosin: a preliminary study to analyze human ejaculation using color Doppler ultrasonography. Int J Urol 2008;15:915–8.
16. Marks L. S., Gittelman M. C., Hill L. A. Rapid efficacy of the highly selective A1-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. J Urol 2009;181:2634–40.
17. Kawabe K., Yoshida M., Homma Y. Silodosin, a new a1A-adrenoceptorselective antagonist for treating benign prostatic hyperplasia: a results of a phase III randomized, placebo-controlled, double-blind study in Japanese men. BJU Int 2006;98:1019–24.
18. Speakman M. J., Snijder R. J., Anthonijs G., Doyle C. A. Patients on tamsulosin experiencing abnormal ejaculation choose to remain longer in clinical trials and have slightly better improvement in symptom score than other patients abstract. J Urol 2003;169(Suppl 4):334.
19. Roehrborn C. G., Lepor H., Kaplan S. A. et al. Retrograde ejaculation induced by silodosin is associated with greater urodynamic and symptomatic improvement in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. Podium presentation at the 85th annual meeting of the Western Section of the American Urological Association, October 25–29, 2009.
20. Lepor G. Al'fa-blokatory: otbor na selektivnost'. Istinno selektivnyi al'fa-blokator. Urol segodnya 2013;3(25):3.
21. Govorov A. V. Al'fa-blokatory: otbor na selektivnost'. Al'fa-blokatory: uroselektivnost' po maksimumu. Urol segodnya 2013;3(25):1–2.
22. Montorsi F. Al'fa-blokatory: otbor na selektivnost'. Al'fa-blokatory: nauka v fokuse. Urol segodnya 2013;3(25):4.
23. Mel'nikov A. V. Posleoperatsionnaya ostraya zaderzhka mocheispuskaniya: Dis. … kand. med. nauk. M., 2002. 136 c.
24. Tatemichi S., Kobayashi K., Maezawa A. et al. α1-Adrenoceptor subtype selectivity and organ specifi city of silodosin (KMD-3213). Yakugaku Zasshi 2006;126:209–16.
25. Watanabe T., Ozono S., Kageyama S. A randomized crossover study comparing patient preference for tamsulosin and silodosin in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia. J Int Med Res 2011; 39(1):129–42.
26. Marks L. S., Gittelman M. C., Hill L. A. et al. Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. J Urol 2009;181(6):2634–40.
27. Chapple C., Montorsi F., Tammela T. et al.; European Silodosin Study Group. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe. Eur Urol 2011;3(59):342–52.
28. Montorsi F. Profile of silodosin. Eur Urol 2010;4(Suppl 9):491–5.
29. Yarovoi S. K. Silodozin – novyi preparat gruppy selektivnykh α1-adrenoblokatorov. Eksper i klin urol 2012;3:57–62.
30. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Diuretic versus alpha-blocker as first-step antihypertensive therapy. Final results from the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Hypertension 2003;42:239–46.
31. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2002;288(23):2981–97.
32. Blaivas J., Marks B., Weiss J. et al. Differential diagnosis of overactive bladder in men. J Urol 2009;182(6):2814–7.
33. Abrams P. H., Farrar D. J., Turner-Warwick R. T. et al. The results of prostatectomy: a symptomatic and urodynamic analysis of 152 patients. J Urol 1979;121:640–2.
34. Gadzhieva Z. K. Urodinamicheskie issledovaniya v diagnostike i lechenii narushenii mocheispuskaniya: Dis. … d-ra med. nauk. M., 2009.
35. Tangriberganov M. R. Osobennosti lecheniya dobrokachestvennoi giperplazii predstatel'noi zhelezy v sochetanii s klinicheskimi simptomami giperaktivnogo mochevogo puzyrya: Dis. … kand. med. nauk. M., 2011.
36. Ohtake A., Ukai M., Hatanaka T. et al. In vitro and in vivo tissue selectivity profile of Solifenacin succinate (YM905) for urinary bladder over salivary gland in rats. Eur J Pharmacol 2004;492:243–50.
37. Chapple C., Herschornb S., Abrams P. et al. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers. Eur Urol 2009;56(3):534–41.
38. Abdel-Khalek M., Nabieh A., Ibrahiem E. Do muscarinic receptors of the prostate have a significant role in the pathophysiology of bladder outlet obstruction? phase 1 (in vitro) study. Eur Urol Suppl 2006;5(2):120.
39. Kozyrev S. V. Diagnostika i lechenie giperaktivnogo mochevogo puzyrya u bol'nykh dobrokachestvennoi giperplaziei predstatel'noi zhelezy: Dis. … kand. med. nauk. M., 2008.
40. Saito H., Yamada T., Oshima H. et al. A comparative study of the efficacy and safety of tamsulosin hydrochloride alone and combination of propiverine hydrochloride and tamsulosin hydrochloride in the benign prostatic hypertrophy with pollakisuria and / or urinary incontinence. Jpn J Urol Surg 1999;12:525–36.
41. Athanasopoulos A., Gyftopoulos K., Giannitsas K. et al. Combination treatment with an α-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J Urol 2003;169:2253–6.
42. Lee K. S., Kim D. Y., Kim J. C. et al. Combination treatment with propiverine hydrochloride plus doxazosin gits in men with overactive bladder coexisting benign prostatic obstruction: a prospective, randomized, controlled, multicenter study. ICS annual meeting, 2004 (abstr. 207).
43. Lee K. S., Choo M. S., Kim D. Y. et al. Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and
44. coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study. J Urol 2005;174:1334–8.
45. Kaplan S. A., Roehrborn C. G., Rovner E. S. et al. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA 2006;296 (19):2319–28.
46. MacDiarmid S.A., Peters K. M., Chen A. et al. Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study. Mayo Clin Proc 2008;83(9): 1002–10.
47. Drake M., Chapple C., van Kerrebroeck P. et al. Efficacy of combination therapy with tamsulosin OCAS and solifenacin in NEPTUNE: Results from a randomised, phase 3 trial in men with LUTS. Eur Urol 2012; EAU abstracts #746H.
